{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:28:04Z","timestamp":1793525284670,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcf.2024.03.011","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T16:38:02Z","timestamp":1712248682000},"page":"1122-1128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Elexacaftor\/Tezacaftor\/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8432-6113","authenticated-orcid":false,"given":"Hannah E","family":"Protich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8708-0298","authenticated-orcid":false,"given":"Jean P","family":"Molleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6049-0481","authenticated-orcid":false,"given":"Rebecca S","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.03.011_bib0001","unstructured":"Cystic Fibrosis Foundation patient registry 2021 annual data report. \u201cCystic fibrosis foundation\u201d. Published September 2022. Accessed March 20th, 2023. Available from: https:\/\/www.cff.org\/medical-professionals\/patient-registry."},{"issue":"4","key":"10.1016\/j.jcf.2024.03.011_bib0002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ccm.2022.06.002","article-title":"Toward a broader understanding of cystic fibrosis epidemiology and its impact on clinical manifestations","volume":"43","author":"McBennett","year":"2022","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.03.011_bib0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cld.2018.12.008","article-title":"Hepatic manifestations of cystic fibrosis","volume":"23","author":"Sakiani","year":"2019","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.jcf.2024.03.011_bib0004","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic Fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.03.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcf.2024.03.011_bib0006","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/MPG.0000000000003194","article-title":"Survival benefits following liver transplantation: a matched-pair analysis in pediatric patients with cystic fibrosis","volume":"73","author":"Flemming","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.03.011_bib0007","article-title":"Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension: prospective long-term results","author":"Hermie","year":"2023","journal-title":"Diagn Interv Radiol"},{"issue":"12","key":"10.1016\/j.jcf.2024.03.011_bib0008","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jcf.2024.03.011_bib0009","article-title":"Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations","author":"Sellers","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jcf.2024.03.011_bib0010","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","volume":"9","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.jcf.2024.03.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000222.pub3","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","author":"Cheng","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.jcf.2024.03.011_bib0012","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with Cystic Fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.03.011_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-label clinical trial of Elexacaftor\/Tezacaftor\/Ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.jcf.2024.03.011_bib0014","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for Cystic Fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2024.03.011_bib0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic Fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.03.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for treatment of Cystic Fibrosis","volume":"65","author":"Despotes","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.jcf.2024.03.011_bib0017","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid Improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with Cystic Fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.03.011_bib0018","doi-asserted-by":"crossref","first-page":"e0010","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.jcf.2024.03.011_bib0019","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s13318-022-00791-8","article-title":"Phase 1 study to assess the safety and pharmacokinetics of Elexacaftor\/Tezacaftor\/Ivacaftor in subjects without cystic fibrosis with moderate hepatic impairment","volume":"47","author":"Viswanathan","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.jcf.2024.03.011_bib0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jcf.2020.07.014","article-title":"Biliary disease and cholecystectomy after initiation of elexacaftor\/ivacaftor\/tezacaftor in adults with cystic fibrosis","volume":"20","author":"Safirstein","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.03.011_bib0021","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.03.011_bib0022","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: when it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.03.011_bib0023","unstructured":"Trikafta (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor). [Product information]. Boston: vertex Pharmaceuticals, April 2023. Accessed May 13, 2023."},{"key":"10.1016\/j.jcf.2024.03.011_bib0024","unstructured":"Kalydeco (ivacaftor). [Product information]. Boston: vertex pharmaceuticals, May 2023. Accessed May 13, 2023."},{"key":"10.1016\/j.jcf.2024.03.011_bib0025","unstructured":"Orkambi (lumacaftor\/ivacaftor). [Product information]. Boston: vertex pharmaceuticals, September 2022. Accessed May 13, 2023."},{"key":"10.1016\/j.jcf.2024.03.011_bib0026","unstructured":"Symdeko (tezacaftor\/ivacaftor). [Product information]. Boston: vertex pharmaceuticals, June 2022. Accessed May 13, 2023."},{"key":"10.1016\/j.jcf.2024.03.011_bib0027","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"issue":"2","key":"10.1016\/j.jcf.2024.03.011_bib0028","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPG.0000000000002383","article-title":"Antimicrobials and antiepileptics are the leading causes of idiosyncratic drug-induced Liver Injury in American Children","volume":"69","author":"DiPaola","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.03.011_bib0029","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed: March 29, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548157\/."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:33:02Z","timestamp":1793521982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1569199324000407"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.03.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/Tezacaftor\/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}